# Adam Rosenthal

> Adam Rosenthal is the CEO and Founder of Star Therapeutics, a clinical-stage biotech he launched in 2018 with a mission to develop life-changing therapies for rare diseases. An MIT and Harvard-trained biomedical engineer, Rosenthal built Star around the insight that shared biology across multiple rare diseases can yield single therapies addressing many conditions at once. His lead asset VGA039 - a first-in-class monoclonal antibody targeting Protein S - entered Phase 3 trials in 2025 for von Willebrand disease, the most common inherited bleeding disorder. Star has raised over $315 million from top-tier life sciences investors including Sanofi Ventures and Viking Global Investors.

- **Role:** CEO and Founder at Star Therapeutics
- **Organizations:** Star Therapeutics, Electra Therapeutics, Vega Therapeutics
- **Nationality:** American
- **Education:** BS in Electrical Engineering, Massachusetts Institute of Technology, BS in Brain and Cognitive Science, Massachusetts Institute of Technology, MEng in Electrical Engineering and Computer Science, Massachusetts Institute of Technology, PhD in Biomedical Engineering, Massachusetts Institute of Technology / Harvard University
- **Known for:** Founded Star Therapeutics in 2018, raising over $315M from top-tier investors by 2025, Led True North Therapeutics to $825M acquisition by Bioverativ, Contributed to iPierian's $725M acquisition by Bristol-Myers Squibb

## Career timeline

- **~2000s** — Project Leader at Boston Consulting Group
- **~2010s** — Vice President, Head of Corporate Development at iPierian (acquired by Bristol-Myers Squibb for $725M)
- **~2013-2017** — Chief Business Officer at True North Therapeutics; raised $140M+ in private financing; company acquired by Bioverativ for $825M
- **2018** — Founded Star Therapeutics and co-founded Electra Therapeutics
- **2022** — Star Therapeutics emerges from stealth with $100M raised; Electra Therapeutics publicly launched
- **2022** — Star Therapeutics adds $90M Series C; spins out Vega Therapeutics
- **2024** — VGA039 interim Phase 1/2 data presented at ASH Annual Meeting showing substantial bleed reductions
- **2025-01** — VGA039 receives FDA Fast Track Designation for von Willebrand Disease
- **2025-09** — Star Therapeutics closes oversubscribed $125M Series D co-led by Sanofi Ventures and Viking Global; Phase 3 VIVID-6 trial initiated

## Achievements

- Founded Star Therapeutics in 2018, raising over $315M from top-tier investors by 2025
- Led True North Therapeutics to $825M acquisition by Bioverativ
- Contributed to iPierian's $725M acquisition by Bristol-Myers Squibb
- Designed and executed hub-and-spoke biotech model, spinning out Electra Therapeutics and Vega Therapeutics as independent clinical-stage companies
- Secured FDA Fast Track Designation for VGA039 in von Willebrand Disease (January 2025)
- Initiated Phase 3 VIVID-6 trial for VGA039, potentially the first subcutaneous therapy addressing all types of VWD
- Raised oversubscribed $125M Series D co-led by Sanofi Ventures and Viking Global Investors (September 2025)
- Holds advanced degrees from MIT and Harvard in electrical engineering, brain science, and biomedical engineering

## Latest updates

- **2025-09** — Star Therapeutics closes oversubscribed $125M Series D; Phase 3 VIVID-6 trial for VGA039 initiated for all types of VWD
- **2025-01** — VGA039 receives FDA Fast Track Designation for von Willebrand Disease
- **2024-12** — Interim Phase 1/2 data for VGA039 presented at ASH 2024, showing substantial bleed reductions in all patients across all types of VWD

## Links

- Website: https://star-therapeutics.com
- LinkedIn: http://www.linkedin.com/in/adam-rosenthal-2013109
- Twitter/X: https://twitter.com/STAR_Biotech

---

Profile page: https://yespress.io/adam-rosenthal
Published by YesPress — https://yespress.io
Last updated: 2026-05-13